TGFBR1*6A is a common hypomorphic variant of the type I
transforming growth factor (
TGF)-beta receptor (
TGFBR1), which transduces
TGF-beta growth inhibitory signals less effectively than
TGFBR1. Recent studies suggest that
TGFBR1*6A confers a selective growth advantage to both normal appearing and cancerous epithelial cells in the presence of
TGF-beta. We have previously shown that
TGFBR1*6A is somatically acquired in head and neck and
colon cancer (10). Using microdissected tissues, we show that
TGFBR1*6A is somatically acquired by stromal and epithelial cells adjacent to colorectal and head and neck
tumors. Somatic acquisition of the
TGFBR1*6A allele is not accompanied by acquisition of other
tumor-specific mutations. Furthermore, lymphocytes located within the stroma or the normal appearing epithelium do not have evidence of
TGFBR1*6A acquisition. The highest
TGFBR1*6A/
TGFBR1 allelic ratio is observed at the
tumor's edge, and traces of
TGFBR1*6A are detected as far
as 2 cm away from the
tumor, which is suggestive of centrifugal spread of cells that harbor
TGFBR1*6A. Assessment of CDH1 and CDH2 expression does not indicate epithelial-mesenchymal transformation. The results suggest that
TGFBR1*6A somatic acquisition is a critical event in the early stages of
cancer development that is associated with field cancerization. They also represent the first human report of somatically acquired altered stromal
TGF-beta signaling during
oncogenesis and the first report of a concordant mutation in the stromal and epithelial compartments in
colon cancer.